A board-certified radiation oncologist, David Raben, M.D. is currently the CMO at Bicara Therapeutics with more than 25 years of academic translational oncology experience and 4 years in pharma, having most recently served as vice president of global product development and product general manager, oncology, at Amgen. At Amgen, his work centered on driving the anti-DLL3 program in neuroendocrine cancers. Prior to that, Dr. Raben served as vice president and franchise leader, clinical development oncology, at Genentech, focusing on precision medicine and immunotherapy trials in head and neck and thoracic cancer, in both late-stage and locally advanced settings. His career started at the Univ. of Alabama at Birmingham for 1994-1998 followed by over 20 years as a professor and member of the University of Colorado Cancer Center, where his main areas of focus included evaluating and combining novel biologic therapies for patients with locally advanced cancers of the head and neck (HNC) and lung. His expertise also includes translational experience in areas such as EGFR signaling, DNA damage repair, TGFb and checkpoint inhibition. Nationally, Dr. Raben served on the NRG Oncology Head and Neck Cancer (HNC) steering committee for the past 15 years and established and led the Radiation Developmental Therapeutics Committee at the NRG. He remains an active member of the American Head and Neck Society, IASLC, ESMO, AACR and ASTRO and currently serves on the ASCO Research committee. Dr. Raben holds a Batchelor of Arts degree from Duke University and earned his M.D. from Wake Forest University. He completed residency training in Radiation Oncology at the John Hopkins Hospital.
